about
Multimorbidity prevalence in the general population: the role of obesity in chronic disease clusteringComparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population.Weight loss required by the severely obese to achieve clinically important differences in health-related quality of life: two-year prospective cohort studyDeterminants of lifestyle behavior in type 2 diabetes: results of the 2011 cross-sectional survey on living with chronic diseases in CanadaMental health and the relationship between health promotion counseling and health outcomes in chronic conditions: cross-sectional population-based study.Prompted awareness and use of Eating Well with Canada's Food Guide: a population-based study.Health Behaviours and Awareness of Canada's Food Guide: A Population-based Study.The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione.Multimorbidity in a prospective cohort: prevalence and associations with weight loss and health status in severely obese patients.Self-monitoring of blood glucose in type 2 diabetes: Results of the 2011 Survey on Living with Chronic Diseases in Canada.Association between Epstein-Barr virus infection and risk for development of pregnancy-associated breast cancer: joint effect with vitamin D?Weight loss and outcomes in wait-listed, medically managed, and surgically treated patients enrolled in a population-based Bariatric program: prospective cohort study.Predictors of health-related quality of life in 500 severely obese patients.Health-related quality of life and healthcare utilization in multimorbidity: results of a cross-sectional survey.Population-level response shift: novel implications for research.Serum 25-hydroxyvitamin D and the risk of ovarian cancer.Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal studySerum 25-hydroxyvitamin D at pregnancy and risk of breast cancer in a prospective study
P50
Q33642098-5B8ACF26-0EA5-47D3-A588-4A5F113C8B64Q33646326-C4C65A5D-9715-45F3-9090-EB4D51FB693CQ34416944-2119ABFC-F154-4B72-8109-3446383D5045Q34707547-0D780F2C-55C8-4FDE-89DC-45F5513BF36DQ37580576-3DE02783-75DB-4484-B9AC-2BDA89EF44DEQ39242601-A1F04AC2-0BF1-4F28-B68D-4E65EC429D15Q40103564-8143D43C-B660-4789-992A-689FD9B3FA64Q43204364-0000FDC6-E57A-4484-B5AD-7C2AA6F7BE66Q43894592-694CD1BA-73FE-456D-BBC2-3E4BFB2741BAQ44154362-DD38E0D0-2D2A-4E16-A40C-BCF848931387Q45373895-DCA66327-E0BF-403A-BD79-320BCCD4F085Q47191728-AC52F1BA-FEDF-4646-B90D-F3D721664250Q48098480-1E94CCDC-DB89-46C6-95B1-675DF82DCAAFQ48430894-66376F8C-CCB8-4B0C-9AC8-9F094A612337Q48542897-D3865423-800F-4F22-AC0C-3D1CE94F40D6Q51651459-71DC8579-764B-4482-BEFF-9FACACF633D7Q58352138-CC2612B7-BE69-4816-9A91-7E8B677364ACQ60445766-FB89B02B-7345-4440-A778-AC1B9F50FED2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Calypse Agborsangaya
@ast
Calypse Agborsangaya
@en
Calypse Agborsangaya
@es
Calypse Agborsangaya
@nl
Calypse Agborsangaya
@sl
type
label
Calypse Agborsangaya
@ast
Calypse Agborsangaya
@en
Calypse Agborsangaya
@es
Calypse Agborsangaya
@nl
Calypse Agborsangaya
@sl
prefLabel
Calypse Agborsangaya
@ast
Calypse Agborsangaya
@en
Calypse Agborsangaya
@es
Calypse Agborsangaya
@nl
Calypse Agborsangaya
@sl
P106
P31
P496
0000-0002-0249-533X